BridgeBio Pharma Inc (BBIO)
25.59
+0.11
(+0.43%)
USD |
NASDAQ |
Nov 04, 13:00
BridgeBio Pharma Gross Profit Margin (Quarterly): 72.42% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 72.42% |
| March 31, 2024 | 99.72% |
| December 31, 2023 | 65.73% |
| September 30, 2023 | 85.38% |
| June 30, 2023 | 63.50% |
| March 31, 2023 | 64.35% |
| December 31, 2022 | 65.40% |
| September 30, 2022 | -118.6% |
| June 30, 2022 | 99.05% |
| March 31, 2022 | 20.42% |
| Date | Value |
|---|---|
| December 31, 2021 | 87.96% |
| September 30, 2021 | 37.97% |
| June 30, 2021 | 99.80% |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | 90.65% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-118.6%
Minimum
Sep 2022
99.80%
Maximum
Jun 2021
57.16%
Average
65.73%
Median
Dec 2023
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 82.85% |
| Pfizer Inc | 70.27% |
| Vertex Pharmaceuticals Inc | 85.94% |
| PTC Therapeutics Inc | 91.68% |
| Bristol-Myers Squibb Co | 75.13% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -67.76% |
| Return on Invested Capital | -87.43% |
| Profit Margin (Quarterly) | -3.39K% |
| Operating Margin (Quarterly) | -7.96K% |
| Return on Net Operating Assets | -468.5% |